Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Feasibility of including cellular telephone numbers in random digit dialing for epidemiologic case-control studies.

Voigt LF, Schwartz SM, Doody DR, Lee SC, Li CI.

Am J Epidemiol. 2011 Jan 1;173(1):118-26. doi: 10.1093/aje/kwq322. Epub 2010 Nov 11.

2.

Risk factors for triple-negative breast cancer in women under the age of 45 years.

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1157-66. doi: 10.1158/1055-9965.EPI-08-1005. Epub 2009 Mar 31.

3.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139
4.

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.

Breast Cancer Res Treat. 2009 Jan;113(2):357-70. doi: 10.1007/s10549-008-9926-3. Epub 2008 Mar 7.

PMID:
18324472
5.
6.

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.

Hum Pathol. 2006 Sep;37(9):1217-26. Epub 2006 Jul 18.

PMID:
16938528
7.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.

PMID:
16757721
8.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
9.

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators.

JAMA. 2003 Jun 25;289(24):3243-53.

PMID:
12824205
10.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74.

11.

Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives.

Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, Dent D, Gudgeon A, van Zyl J, Katzenellenbogen J, Baillie R.

Am J Epidemiol. 2000 Feb 15;151(4):396-403. Erratum in: Am J Epidemiol 2000 Jun 1;151(11):1134.

13.

Pharmacokinetics of depot medroxyprogesterone acetate contraception.

Mishell DR Jr.

J Reprod Med. 1996 May;41(5 Suppl):381-90. Review.

PMID:
8725700
15.

A case-control study of breast cancer and hormonal contraception in Costa Rica.

Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ.

J Natl Cancer Inst. 1987 Dec;79(6):1247-54.

PMID:
2961909
16.

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

Paul C, Skegg DC, Spears GF.

BMJ. 1989 Sep 23;299(6702):759-62.

18.
19.

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR.

J Clin Endocrinol Metab. 1977 Jan;44(1):32-8.

PMID:
833262
Items per page

Supplemental Content

Write to the Help Desk